These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 20888494)
1. Dupuytren's fibroblast contractility by sphingosine-1-phosphate is mediated through non-muscle myosin II. Komatsu I; Bond J; Selim A; Tomasek JJ; Levin LS; Levinson H J Hand Surg Am; 2010 Oct; 35(10):1580-8. PubMed ID: 20888494 [TBL] [Abstract][Full Text] [Related]
2. Correlation of alpha-smooth muscle actin expression and contraction in Dupuytren's disease fibroblasts. Tomasek J; Rayan GM J Hand Surg Am; 1995 May; 20(3):450-5. PubMed ID: 7642925 [TBL] [Abstract][Full Text] [Related]
3. Calcium-dependent signaling in Dupuytren's disease. Hadeed JG; Bond JE; Selim MA; Bergeron A; Levin LS; Levinson H Hand (N Y); 2011 Jun; 6(2):159-64. PubMed ID: 22654698 [TBL] [Abstract][Full Text] [Related]
4. Tamoxifen decreases fibroblast function and downregulates TGF(beta2) in dupuytren's affected palmar fascia. Kuhn MA; Wang X; Payne WG; Ko F; Robson MC J Surg Res; 2002 Apr; 103(2):146-52. PubMed ID: 11922728 [TBL] [Abstract][Full Text] [Related]
5. Dupuytren's disease susceptibility gene, EPDR1, is involved in myofibroblast contractility. Staats KA; Wu T; Gan BS; O'Gorman DB; Ophoff RA J Dermatol Sci; 2016 Aug; 83(2):131-7. PubMed ID: 27245865 [TBL] [Abstract][Full Text] [Related]
6. Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells. Verjee LS; Midwood K; Davidson D; Eastwood M; Nanchahal J J Cell Physiol; 2010 Sep; 224(3):681-90. PubMed ID: 20432463 [TBL] [Abstract][Full Text] [Related]
7. Increased CCT-eta expression is a marker of latent and active disease and a modulator of fibroblast contractility in Dupuytren's contracture. Satish L; O'Gorman DB; Johnson S; Raykha C; Gan BS; Wang JH; Kathju S Cell Stress Chaperones; 2013 Jul; 18(4):397-404. PubMed ID: 23292503 [TBL] [Abstract][Full Text] [Related]
8. Dupuytren's disease: physiologic changes in nodule and cord fibroblasts through aging in vitro. Moyer KE; Banducci DR; Graham WP; Ehrlich HP Plast Reconstr Surg; 2002 Jul; 110(1):187-93; discussion 194-6. PubMed ID: 12087251 [TBL] [Abstract][Full Text] [Related]
9. The effect of interferon-alpha2b on an in vitro model Dupuytren's contracture. Sanders JL; Dodd C; Ghahary A; Scott PG; Tredget EE J Hand Surg Am; 1999 May; 24(3):578-85. PubMed ID: 10357539 [TBL] [Abstract][Full Text] [Related]
10. Pharmacologic regulation of Dupuytren's fibroblast contraction in vitro. Rayan GM; Parizi M; Tomasek JJ J Hand Surg Am; 1996 Nov; 21(6):1065-70. PubMed ID: 8969433 [TBL] [Abstract][Full Text] [Related]
11. Differences in alpha smooth muscle actin expression between fibroblasts derived from Dupuytren's nodules or cords. Dave SA; Banducci DR; Graham WP; Allison GM; Ehrlich HP Exp Mol Pathol; 2001 Oct; 71(2):147-55. PubMed ID: 11599921 [TBL] [Abstract][Full Text] [Related]
12. The collagen changes of Dupuytren's contracture. Murrell GA; Francis MJ; Bromley L J Hand Surg Br; 1991 Aug; 16(3):263-6. PubMed ID: 1960490 [TBL] [Abstract][Full Text] [Related]
13. Expression of bone morphogenetic proteins by Dupuytren's fibroblasts. Shin SS; Liu C; Chang EY; Carlson CS; Di Cesare PE J Hand Surg Am; 2004 Sep; 29(5):809-14. PubMed ID: 15465229 [TBL] [Abstract][Full Text] [Related]
14. An insight into Dupuytren's contracture. Murrell GA Ann R Coll Surg Engl; 1992 May; 74(3):156-60; discussion 161. PubMed ID: 1616255 [TBL] [Abstract][Full Text] [Related]